Exploring BAFF: Its expression, receptors and contribution to the immunopathogenesis of Sjögren's syndrome

Rheumatology (United Kingdom)

Volumn 55, Issue 9, 2016, Pages 1548-1555

  Thompson, Nicolyn ^a   Isenberg, David A ^a   Jury, Elizabeth C ^a   Ciurtin, Coziana ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

B cell activating factor (BAFF); BAFF receptor; Sj gren's syndrome

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; CYTOKINE; TNFSF13B PROTEIN, HUMAN;

ANTIBODY PRODUCTION; B LYMPHOCYTE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SJOEGREN SYNDROME; SYSTEMIC DISEASE; ANIMAL; B LYMPHOCYTE SUBPOPULATION; BIOSYNTHESIS; DISEASE MODEL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MEMBRANE MICRODOMAIN; METABOLISM; PATHOLOGY; PHYSIOLOGY; SJOGREN'S SYNDROME;

ANIMALS; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE MICRODOMAINS; SJOGREN'S SYNDROME;

EID: 84995582047     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev420     Document Type: Review

References (53)

1. Voulgarelis MA, Tzioufas G. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol 2010;6:529-37.
2. Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 1984;14:77-105.
3. Patel R, Shahane A. The epidemiology of Sjögren's syndrome. Clin Epidemiol 2014;6:247
4. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013;9:544-56.
5. Roberts ME, Kaminski D, Jenks SA et al. Primary Sjögren's syndrome is characterized by distinct phenotypic and transcriptional profiles of IgD+ unswitched memory B cells. Arthritis Rheumatol 2014;66:2558-69.
6. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75.
7. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013;24:203-15.
8. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9:491-502.
9. Youinou P, Pers JO. Disturbance of cytokine networks in Sjögren's syndrome. Arthritis Res Ther 2011;13:227
10. Manetta J, Bina H, Ryan P et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res 2014;7:121-31
11. Ittah M, Miceli-Richard C, Gottenberg J-E et al. B cellactivating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther 2006;8:R51.
12. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005;17:282-9.
13. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-75.
14. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9.
15. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
16. Vairo G, Hamilton JA. CSF-1 stimulates Na+K+-ATPase mediated 86Rb+ uptake in mouse bone marrow-derived macrophages. Biochem Biophys Res Commun 1985;132:430-7.
17. Gavin AL, Duong B, Skog P et al. deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 2005;175:319-28.
18. Le Pottier L, Pers J-O, MacKay F, Youinou P. Delta4BAFF, an alternative-splice isoform that acts as a transcription factor to enhance BAFF production in auto-immunity and cancer. 2010.
19. Gavin AL, Aït-Azzouzene D, Ware CF, Nemazee D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003;278:38220-8.
20. Ng LG, Sutherland AP, Newton R et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807-17.
21. Jeon ST, Kim WJ, Lee SM et al. Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunol Cell Biol 2010;88:148-56.
22. Crupi R, Cambiaghi M, Deckelbaum R et al. n-3 fatty acids prevent impairment of neurogenesis and synaptic plasticity in B-cell activating factor (BAFF) transgenic mice. Prevent Med 2012;54(Suppl):S103-8.
23. Fletcher CA, Sutherland APR, Groom JR et al. Development of nephritis but not sialadenitis in autoimmune prone BAFF transgenic mice lacking marginal zone B cells. Eur J Immunol 2006;36:2504-14.
24. Batten M, Fletcher C, Ng LG et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004;172:812-22.
25. Qian Y, Qin J, Cui G et al. Act1, a negative regulator in CD40-and BAFF-mediated B cell survival. Immunity 2004;21:575-87.
26. Qian Y, Giltiay N, Xiao J et al. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. Eur J Immunol 2008;38:2219-28.
27. Lavie F, Miceli-Richard C, Ittah M et al. B cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand J Immunol 2008;67:185-92.
28. Litinskiy MB, Nardelli B, Hilbert DM et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9.
29. Huang YF, Cheng Q, Jiang CM et al. The immune factors involved in the pathogenesis, diagnosis, and treatment of Sjogren's syndrome. Clin Dev Immunol 2013;2013:160491
30. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68.
31. Li H, Ice JA, Lessard CJ, Sivils KL et al. Interferons in Sjögren's syndrome: genes, mechanisms, and effects. Front Immunol 2013;4:290.
32. Daridon C, Pers JO, Devauchelle V et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2006;54:2280-8.
33. Yoshimoto K, Tanaka M, Kojima M et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren's syndrome. Arthritis Res Ther 2011;13:R170.
34. Bohnhorst JØ, Bjørgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. J Immunol 2001;167:3610-8.
35. d'Arbonneau F, Pers JO, Devauchelle V et al. BAFF induced changes in B cell antigen receptor-containing lipid rafts in Sjögren's syndrome. Arthritis Rheum 2006;54:115-26.
36. Binard A, Le Pottier L, Devauchelle-Pensec V et al. Is the blood B-cell subset profile diagnostic for Sjögren syndrome? Ann Rheum Dis 2009;68:1447-52
37. Lin W, Jin L, Chen H et al. B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjogren's syndrome: the similarities and differences. Arthritis Res Ther 2014;16:R118
38. Quartuccio L, Fabris M, Moretti M et al. Resistance to rituximab therapy and local BAFF overexpression in Sjö gren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2008;2:38-43.
39. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003;62:168-71.
40. Takahata H, Ohara N, Ichimura K et al. BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas. J Clin Exp Hematop 2010;50:121-7.
41. Suzuki K, Setoyama Y, Yoshimoto K et al. Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells. Cytokine 2008;44:44-8.
42. Papageorgiou A, Mavragani CP, Nezos A et al. A BAFF receptor His159Tyr mutation in Sjogren's syndrome related lymphoproliferation. Arthritis Rheumatol 2015;67:2732-41.
43. Lahiri A, Varin MM, Le Pottier L et al. Specific forms of BAFF favor BAFF receptor-mediated epithelial cell survival. J Autoimmun 2014;51:30-7.
44. Dong L, Masaki Y, Takegami T et al. Clonality analysis of lymphoproliferative disorders in patients with Sjögren's syndrome. Clin Exp Immunol 2007;150:279-84.
45. Goenka R, Matthews AH, Zhang B, et al. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med 2014;211:45-56.
46. Nezos A, Papageorgiou A, Fragoulis G et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun 2014;51:89-98.
47. Gupta N, DeFranco AL. Lipid rafts and B cell signaling. Semin Cell Dev Biol 2007;18:616-26.
48. Flores Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2007;56:291-302.
49. Infantino S, Tarlinton DM. Feeling a Little SYK after Mixing BAFF with BCR. Immunity 2013;38:406-8.
50. Pham LV, Tamayo AT, Yoshimura LC et al. A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 2002;16:37-50.
51. Quartuccio L, Salvin S, Fabris M et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology 2013;52:276-81.
52. Mariette X, Seror R, Quartuccio L et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015;74:526-31.
53. Pontarini E, Fabris M, Quartuccio L et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. Rheumatology 2015;54:1429-34.